Verrica Pharmaceuticals Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 07/11/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $35.6M | $7.6M | $5.1M | $9.0M | — |
| Cost of revenue | — | $2.6M | $500,000 | — | — |
| Selling, general & administrative | $35.2M | $58.8M | $47.3M | $17.4M | — |
| Research and development | $8.9M | $11.8M | $20.3M | $12.2M | — |
| Operating expenses | $47.8M | $73.5M | $70.9M | $30.3M | — |
| Operating income | -$12.2M | -$65.9M | -$65.8M | -$21.3M | — |
| Interest expense | $7.7M | $9.4M | $4.0M | $2.2M | — |
| Income tax expense | $0 | $0 | $0 | $0 | — |
| Net income | -$17.9M | -$76.6M | -$67.0M | -$24.5M | — |
| Balance Sheet | |||||
| Cash and equivalents | $30.1M | $46.3M | $69.5M | $34.3M | — |
| Current assets | $42.5M | $51.2M | $77.5M | $39.1M | — |
| Total assets | $47.1M | $54.1M | $81.6M | $44.7M | — |
| Current liabilities | $16.4M | $29.0M | $17.0M | $3.5M | — |
| Total liabilities | $22.4M | $64.0M | $61.8M | $4.7M | — |
| Total debt | — | — | — | — | $3.8M |
| Stockholders' equity | $24.7M | -$9.9M | $19.8M | $40.0M | — |
| Cash Flow Statement | |||||
| Cash from operations | -$17.6M | -$60.9M | -$38.6M | -$18.6M | — |
| Depreciation and amortization | $133,000 | $342,000 | $530,000 | $454,000 | — |
| Stock-based compensation | $3.3M | $7.2M | $14.4M | $5.0M | — |
| Capital expenditure | $0 | $27,000 | $362,000 | $302,000 | — |
| Free cash flow | -$17.6M | -$61.0M | -$38.9M | -$19.0M | — |
Shares outstanding 17.2M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.